Who are LENOGRASTIM (GRANOGYTE 34)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pegfilgrastim-Cbqv, PEG-G-CSF, Neulasta® (pegfilgrastim), Filgrastim-sndz, Filgrastim (Eurofarma), PEG-rhG-GSF.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lenograstim-granogyte-34.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

LENOGRASTIM (GRANOGYTE 34) — Competitive Intelligence Brief

LENOGRASTIM (GRANOGYTE 34) (LENOGRASTIM (GRANOGYTE 34)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Granulocyte colony-stimulating factor (G-CSF). Area: Oncology, Hematology.

marketed Granulocyte colony-stimulating factor (G-CSF) G-CSF receptor (GCSFR) Oncology, Hematology Small molecule Live · refreshed every 30 min

Target snapshot

LENOGRASTIM (GRANOGYTE 34) (LENOGRASTIM (GRANOGYTE 34)) — Sanofi. Lenograstim is a recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the proliferation and differentiation of neutrophil precursor cells in bone marrow.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
LENOGRASTIM (GRANOGYTE 34) TARGET	LENOGRASTIM (GRANOGYTE 34)	Sanofi	marketed	Granulocyte colony-stimulating factor (G-CSF)	G-CSF receptor (GCSFR)
Pegfilgrastim-Cbqv	Pegfilgrastim-Cbqv	Coherus Oncology, Inc.	marketed	Granulocyte colony-stimulating factor (G-CSF) analog	G-CSF receptor (GCSFR)
PEG-G-CSF	PEG-G-CSF	Sanofi	marketed	Granulocyte colony-stimulating factor (G-CSF) analog	G-CSF receptor (GCSFR)
Neulasta® (pegfilgrastim)	Neulasta® (pegfilgrastim)	Amgen	marketed	Granulocyte colony-stimulating factor (G-CSF) analog	G-CSF receptor (GCSFR)
Filgrastim-sndz	Filgrastim-sndz	M.D. Anderson Cancer Center	marketed	Granulocyte colony-stimulating factor (G-CSF) analog	G-CSF receptor (GCSFR)
Filgrastim (Eurofarma)	Filgrastim (Eurofarma)	Eurofarma Laboratorios S.A.	phase 3	Granulocyte colony-stimulating factor (G-CSF)	G-CSF receptor (CSF3R)
PEG-rhG-GSF	PEG-rhG-GSF	The First Affiliated Hospital with Nanjing Medical University	phase 3	Granulocyte colony-stimulating factor (G-CSF) analog	G-CSF receptor (GCSFR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Granulocyte colony-stimulating factor (G-CSF) class)

Dong-A ST Co., Ltd. · 2 drugs in this class
M.D. Anderson Cancer Center · 2 drugs in this class
Eurofarma Laboratorios S.A. · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LENOGRASTIM (GRANOGYTE 34) — Competitive Intelligence Brief. https://druglandscape.com/ci/lenograstim-granogyte-34. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab